Preprint Concept Paper Version 1 This version is not peer-reviewed

Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite

Version 1 : Received: 26 April 2018 / Approved: 27 April 2018 / Online: 27 April 2018 (09:00:55 CEST)

How to cite: Bulfone, T.C.; Samuel, S.P.; Bickler, P.L.; Lewin, M.R. Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite. Preprints 2018, 2018040358 (doi: 10.20944/preprints201804.0358.v1). Bulfone, T.C.; Samuel, S.P.; Bickler, P.L.; Lewin, M.R. Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite. Preprints 2018, 2018040358 (doi: 10.20944/preprints201804.0358.v1).

Abstract

The World Health Organization (WHO) recently added snakebite envenoming to the priority list of Neglected Tropical Diseases (NTD). It is thought that ~75% of mortality following snakebite occurs outside the hospital setting, making the temporal gap between a bite and antivenom administration a major therapeutic challenge. Small molecule therapeutics (SMTs) have been proposed as potential pre-referral treatments for snakebite to help address this gap. Herein, we discuss the characteristics, potential uses and development of SMTs as potential treatments for snakebite envenomation. We focus on SMTs that are secretory phospholipase A2 (sPLA2) inhibitors and metalloprotease (MP) inhibitors.

Subject Areas

snakebite; antidote; inhibitor; small molecule therapeutics; SMT; secretory phospholipase; sPLA2; Neglected Tropical Disease; NTD

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.